Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Other Non-Current Liabilities: 2010-2024

Historic Other Non-Current Liabilities for Altimmune (ALT) over the last 14 years, with Dec 2024 value amounting to $5.3 million.

  • Altimmune's Other Non-Current Liabilities rose 22188.46% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.8 million, marking a year-over-year increase of 22188.46%. This contributed to the annual value of $5.3 million for FY2024, which is 13225.00% up from last year.
  • According to the latest figures from FY2024, Altimmune's Other Non-Current Liabilities is $5.3 million, which was up 13,225.00% from $40,000 recorded in FY2023.
  • In the past 5 years, Altimmune's Other Non-Current Liabilities registered a high of $6.1 million during FY2021, and its lowest value of $40,000 during FY2023.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $60,000 (2022), whereas its average is $1.8 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first slumped by 99.01% in 2022, then spiked by 13,225.00% in 2024.
  • Altimmune's Other Non-Current Liabilities (Yearly) stood at $5.4 million in 2020, then rose by 12.99% to $6.1 million in 2021, then tumbled by 99.01% to $60,000 in 2022, then tumbled by 33.33% to $40,000 in 2023, then surged by 13,225.00% to $5.3 million in 2024.